In The News Posted March 7, 2019 Share Posted March 7, 2019 TURKU, Finland, March 7, 2019 /PRNewswire/ -- Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women's health, today announces that it has successfully completed Phase 1a study of FOR-6219, an HSD17B1 inhibitor for the treatment of endometriosis.... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.